BACKGROUND: Prior evidence of a possible link between vitamin D status and hematologic malignancy (HM) in humans comes from observational studies, leaving unresolved the question of whether a true causal relationship exists. METHODS: The authors performed a secondary analysis of data from the Women's Health Initiative Calcium/Vitamin D (CaD) trial, a large randomized controlled trial of CaD supplementation compared with placebo in older women. Kaplan-Meier and Cox proportional hazards survival analysis methods were used to evaluate the relationship between treatment assignment and 1) incident HM and 2) HM-specific mortality over 10 years following randomization. HMs were classified by cell type (lymphoid, myeloid, or plasma cell) and analyzed as distinct endpoints in secondary analyses. RESULTS: A total of 34,763 Women's Health Initiative CaD trial participants (median age, 63 years) had complete baseline covariate data and were eligible for analysis. Women assigned to CaD supplementation had a significantly lower risk of incident HM (hazard ratio [HR], 0.80; 95% confidence interval [95% CI], 0.65-0.99) but not HM-specific mortality (HR, 0.77 [95% CI, 0.53-1.11] for the entire cohort; and HR, 1.03 [95% CI, 0.70-1.51] among incident HM cases after diagnosis). In secondary analyses, protective associations were found to be most robust for lymphoid malignancies, with HRs of 0.77 (95% CI, 0.59-1.01) and 0.46 (95% CI, 0.24-0.89), respectively, for cancer incidence and mortality in those assigned to CaD supplementation. CONCLUSIONS: The current post hoc analysis of data from a large and well-executed randomized controlled trial demonstrates a protective association between modest CaD supplementation and HM risk in older women. Additional research concerning the relationship between vitamin D and HM is warranted.
INTRODUCTION
Vitamin D deficiency may be a modifiable risk factor for hematologic malignancies and may impact survival after diagnosis. Receptors for the active metabolite of vitamin D, hormone 1,25(OH) 2 D 3 , are present in a variety of tissues throughout the body, including hematopoietic cells. Animal and in vitro studies have indicated that 1,25(OH) 2 D 3 has tumorsuppressive functions and contributes to the regulation of cellular differentiation, proliferation, and apoptosis through a variety of mechanisms. Vitamin D deficiency may contribute to carcinogenesis by impairing these normal regulatory processes. [1] [2] [3] [4] To our knowledge to date, the evidence of a link between vitamin D deficiency and hematologic malignancy is observational in nature, and a causal relationship has not been established definitively. Calcium intake also has been associated with a reduced risk of some forms of cancer (eg, colorectal cancer) 5 ; however, to the best of our knowledge, there is currently little epidemiologic or laboratory evidence that would support an effect of calcium intake on the risk of hematologic malignancy.
In the current study, we performed a secondary analysis of data from the Women's Health Initiative (WHI) Calcium/Vitamin D (CaD) trial. The WHI CaD trial was a large randomized controlled trial (RCT) of CaD supplementation in 36,282 older women with a primary endpoint of skeletal fractures and secondary endpoints of incident colorectal cancer and breast cancer. No association was found between CaD trial assignment and the risk of either colorectal or breast cancer. 6, 7 In a subsequent post hoc reanalysis of the WHI CaD trial data, a possible reduction in the risk of breast cancer (hazard ratio [HR] , 0.80) and all invasive cancers (HR, 0.88) was found in women randomized to CaD supplementation who were not receiving calcium or vitamin D supplements at baseline. 8 Data from the WHI CaD trial provide a unique opportunity to augment the existing literature with experimental evidence regarding the effect of CaD supplementation on the risk of incident hematologic cancers and hematologic cancer-specific mortality after diagnosis. We hypothesized that women in the active treatment arm would have a lower risk of both outcomes.
MATERIALS AND METHODS

Study Sample and Follow-Up
The current study was a secondary analysis of data from the WHI randomized trial of CaD supplementation. Enrollment criteria have been described in detail elsewhere. 9, 10 Briefly, participants in the WHI hormone therapy trials and/or diet modification trial were invited to join the CaD trial at the time of their first or second follow-up visits (Fig. 1 ). Women were eligible to participate if they were determined not to be at high risk of adverse events associated with CaD supplementation, study dropout, or poor adherence.
Between 1995 and 2000, a total of 36,282 women were enrolled in the CaD trial and randomized to active treatment (1000 mg of elemental calcium carbonate and 400 IU of vitamin D 3 daily) or placebo (allocation ratio: 1:1). Treatment allocation was determined by a permuted-block algorithm with stratification based on clinic site and participant age. Both participants and research staff were blinded to treatment assignment. The study pills were identical in appearance, and were provided in identical bottles.
Participants took the study medication in 2 divided daily doses, and were advised to take it with a meal. Use of nonstudy dietary supplements of calcium (up to 1000 mg/day) and vitamin D (up to 600 IU/day initially, and then revised upward to 1000 IU/day after the publication of an Institute of Medicine report on the safe upper limits of calcium and vitamin D intake) was allowed. original study cohort still were enrolled, 4% had died, and 3% had either withdrawn from the study or were lost to follow-up. The median length of follow-up was 7 years. After the CaD trial was closed, a total of 29,862 participants (82% of the original cohort) consented to participate in the WHI Extension Study, a 5-year posttrial observational follow-up study. No significant differences by CaD trial assignment were observed with regard to length of follow-up or participation in the WHI Extension Study. 12 In the current study, we analyzed outcomes at 10 years after enrollment in the CaD trial, a median of 3 years after the end of study medication use in the CaD trial. At this time point, approximately 79% of the original study cohort remained enrolled in the WHI Extension Study. In secondary analyses, we censored participants at the end of the WHI CaD trial, when the use of all study medication stopped.
Protection of Human Subjects and Research Ethics
The original WHI CaD trial was approved by the Institutional Review Boards (IRBs) of all participating institutions, and written informed consent was obtained from all trial participants. The WHI studies, including the CaD trial, initially were registered with ClinicalTrials.gov in October 1999 (ClinicalTrials.gov identifier NCT00000611).
This secondary reanalysis of deidentified data from the WHI CaD trial was deemed by the University of Iowa IRB to have IRB exempt status. The study proposal and article were reviewed and approved by the WHI Publications and Presentations Committee.
Exposure to Vitamin D
The primary exposure of interest was the additional vitamin D intake attributable to the trial participants' random assignment to supplementation (400 IU daily) rather than placebo. Baseline data were available for several nonstudy sources of vitamin D, including diet, use of nonstudy nutritional supplements, and sun exposure. Vitamin D intake from dietary sources was estimated from participants' food frequency questionnaire responses. 13 Use of nonstudy vitamin D supplements (yes/no) was characterized based on participant self-report at baseline. Finally, as described below in the covariates section, several proxies for sun exposure and endogenous vitamin D synthesis were considered.
Covariates
Trial, demographic, clinical, and behavioral covariates (Table 1) were identified as potential covariates based on their known or suspected relationship to vitamin D status, the risk of hematologic malignancy, and/or the probability of study dropout. In secondary subgroup analyses, we explored whether factors related to vitamin D status (eg, dietary intake of vitamin D, race, and proxies for sun exposure such as recreational physical activity and latitude) modified the relationship between CaD supplementation and the risk of hematologic malignancy.
Details regarding how covariates were defined are provided in Supporting Information Table 1 . Recreational physical activity was considered as a covariate only in a secondary subgroup analysis because values were missing for approximately 9% of participants. With the exception of study medication adherence, covariates were assessed at the time of WHI enrollment. In a secondary analysis in which we evaluated possible effect modification by degree of adherence, we used participants' study medication adherence at the first year of follow-up to define participants as adherent (took 50% of pills, or on average at least 1 pill daily) or nonadherent, and restricted to participant follow-up that came after this initial adherence assessment.
Outcomes
In the current study, the primary endpoints were 1) incident hematologic malignancy (all types) and 2) hematologic cancer-specific mortality. In secondary analyses of cancer incidence and cancer-specific mortality, we classified hematologic cancers by subtype and considered cases of lymphoid, myeloid, and plasma cell malignancy separately.
Total incident invasive cancers and death from any cause were secondary outcomes in the WHI CaD trial. 14 During the trial period and the Extension Study, all invasive cancers were documented and coded according to primary tumor site. The majority of incident cancers were ascertained through biannual self-report. After the identification of possible cancers by participant or proxy report, reported cancers were physician-adjudicated. Death was ascertained by proxy report and periodic National Death Index linkages. Cause of death was physician-adjudicated based on information in the participant's death certificate, charts from any medical encounters that directly preceded the participant's death, and the autopsy report if available. For both endpoints, adjudication was conducted locally at each study center by a physician, and the adjudication decisions then were reviewed centrally at the WHI Clinical Coordinating Center and coded by trained cancer coders. All adjudicators received extensive training and Original Article were blinded to participants' treatment assignment(s) in the WHI trials. 14 In the current study, participants were followed until the earliest of the following occurred: the occurrence of an endpoint event, year 10 after CaD trial enrollment, the end of the WHI Extension Study (5 years after CaD trial closeout), loss to follow-up, or death unrelated to hematologic malignancy. In a secondary analysis, we censored participants at the time of the CaD trial closeout, when use of the study medication ended.
Statistical Analysis
Nonparametric Kaplan-Meier and Cox proportional hazards regression models were used to assess the association between CaD trial assignment and the risks of 1) incident hematologic malignancy and 2) mortality attributable to hematologic malignancy. Because the primary purpose of the current study was etiologic, we sought to estimate a cause-specific HR for these endpoints, and death due to unrelated causes was treated as a censoring event in these analyses. 15, 16 We also reported absolute risks and risk differences using nonparametric cumulative incidence estimates; to avoid overestimating the absolute risks of the study endpoints, mortality unrelated to hematologic malignancy was treated as a competing risk for the cumulative incidence estimates. 17, 18 All statistical analyses were performed with SAS statistical software (SAS 9.4 for Windows; SAS Institute Inc, Cary, NC).
Because the current study data came from a large RCT of CaD supplementation, we did not anticipate meaningful bias due to confounding by measured or unmeasured risk factors. Due to concerns regarding model overfitting and sparse data bias 19 (particularly for secondary subgroup analyses), we present unadjusted HRs ing for a substantial percentage of the participants (8.8%), it was included as a covariate only in the subgroup analysis that was stratified based on recreational physical activity. Second, in the main analyses, participants were analyzed as they were randomized (intent-to-treat) and the authors did not adjust for study medication adherence. Participants were stratified by adherence during the first year of follow-up in a subgroup analysis. b P values reflect the significance of the differences between treatment arms and were based on the Pearson chi-square and Wilcoxon rank sum tests for categorical and continuous covariates, respectively.
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from univariate Cox regression models. However, in sensitivity analyses, we adjusted for potential confounders to evaluate the possibility of bias attributable to covariate imbalance or covariate-dependent censoring.
RESULTS
Descriptive Information
Of the 36,282 women enrolled in the WHI CaD trial, 34,763 (96%) had data for all required covariates, were not diagnosed with a hematologic malignancy before the initiation of the CaD trial, and were eligible for analysis ( Fig. 1) . At CaD trial baseline, the median participant age was 63 years (interquartile range, 57-68 years). Approximately 17% of participants were nonwhite; 28% reported taking nonstudy vitamin D supplements at baseline. Additional cohort characteristics are provided in Table 1 .
A biomarker assessment in a sample of 576 trial participants found that serum 25(OH)D 3 concentrations were nonsignificantly different before randomization (group means of 20.1 ng/mL and 20.8 ng/mL, respectively, in the CaD supplementation and control arms), and were approximately one-third higher among women in the CaD supplementation arm compared with women in the placebo arm at year 2 after randomization (group means of 24.3 ng/mL and 18.2 ng/mL, respectively). 20 
Risk of Incident Hematologic Malignancy
The primary analyses focused on participant outcomes >10 years after CaD randomization, and included a median of 7 on-trial and 3 posttrial years of participant follow-up. During this period, 349 cases of hematologic malignancy were diagnosed, including 44 myeloid malignancies (28 of which were acute myeloid leukemia), 70 plasma cell dyscrasias (60 of which were multiple myeloma), and 235 lymphoid malignancies (including 13 Hodgkin lymphoma, 6 T-cell lymphoma, 152 B-cell lymphoma, and 60 chronic lymphocytic leukemia/small lymphocytic lymphoma cases). A detailed breakdown of all hematologic malignancies by cell lineage is provided in Supporting Information Table 2 . The risk of hematologic malignancy was found to be significantly lower (P 5 0.04, log-rank test) in the intervention arm compared with the control arm (Cox HR, 0.80; 95% confidence interval [95% CI], 0.65-0.99 [P 5.04]; 10-year cumulative incidences: 0.94% vs 1.17%) (Fig. 2) . The HR changed little after covariate adjustment, but was closer to the null after restricting to on-trial follow-up (Fig. 3) (estimates for all covariates are provided in Supporting Information Fig. 1 ). When cancers were analyzed separately by cell type, the HRs were 0.77 (95% CI, 0.59-1.01), 0.71 (95% CI, 0.37-1.38), and 0.90 (95% CI, 0.54-1.49), respectively, for lymphoid, myeloid, and plasma cell malignancies. Subgroup analyses revealed no significant (P<.05) evidence of an effect modification on the ln(HR) scale (Fig. 3) . There was some variation noted with regard to effect estimates across predefined subgroups, but none of these subgroup differences reached statistical significance. Marginally significant (P<.10) interactions with CaD treatment assignment were observed for vitamin D dietary intake and use of vitamin D supplements at baseline (Fig. 3) .
Risk of Mortality Due to Hematologic Malignancy in the Entire Study Cohort
During the study period, 117 participants died of a hematologic malignancy. There was no significant association found between CaD supplementation and hematologic cancer-specific mortality (HR, 0.77; 95% CI, 0.53-1.11 [P 5 0.16]; P 5.15, log-rank test) (see Supporting Information Fig. 2 ). When analyzed separately by cell type, the HRs for cancer-specific mortality were 0.46 (95% CI, 0.24-0.89), 0.83 (95% CI, 0.36-1.92), and 1.16 (95% CI, 0.54-2.50), respectively, for lymphoid, myeloid, and plasma cell malignancies. In subgroup analyses, no tests for interaction reached statistical significance (Fig. 4) .
Risk of Mortality Due to Hematologic Malignancy After Diagnosis
Among participants diagnosed with a hematologic malignancy, there was no association noted between CaD treatment assignment and cancer-specific mortality during the 5 years after diagnosis (HR, 1.03; 95% CI, 0.70-1.51 [P 5.87]; P 5.87, log-rank test) (see Supporting Information Fig. 3 ). When cases of hematologic malignancy were distinguished based on cell type, the cancerspecific mortality HRs after diagnosis were 0.66 (95% CI, 0.32-1.37), 1.24 (95% CI, 0.53-2.87), and 1.39 (95% CI, 0.62-3.09), respectively, for lymphoid, myeloid, and plasma cell malignancies. In subgroup analyses, no tests for interaction reached statistical significance (Fig. 5) .
DISCUSSION
In this secondary analysis of the WHI CaD Trial, we found evidence of a protective effect of CaD supplementation on the risk of hematologic malignancy (HR, 0.80) over 10 years of follow-up. Overall, no significant association with hematologic cancer-specific mortality was found. In secondary analyses evaluating malignancy risk by cancer cell type, protective associations were most consistent for lymphoid malignancies, with trends toward a reduced risk of incident cancer (HR, 0.77) and cancerspecific mortality (HR, 0.46). Although the current study lacked power to detect 5-year survival among cases after diagnosis, the findings for lymphoid malignancies (HR, 0.66; 95% CI, 0.32-1.37) indicate that further research is warranted.
In predefined subgroup analyses, we found evidence of some variation in effect estimates, but no test for interaction reached statistical significance. More pronounced protective associations between CaD active treatment and incident hematologic malignancies generally were observed in subgroups expected to have lower baseline levels of vitamin D (eg, those with low dietary vitamin D intake, those with no use of nonstudy vitamin D supplements, and black women), but also in some groups expected to have higher baseline levels (eg, those with higher levels of recreational physical activity and those living at lower latitudes). Although this pattern suggests that CaD supplementation was more beneficial in those women with greater baseline vitamin D deficiency, sampling variability also may explain these differences.
The majority of prior studies examining vitamin D and hematologic malignancy have focused on lymphoid cancers. In several prior observational studies, sun exposure, which is an important determinant of vitamin D status, has been found to be inversely associated with the risk of non-Hodgkin lymphoma (NHL). In a pooled analysis of 8243 NHL cases and 9697 controls, 21 higher lifetime recreational sun exposure was associated with a lower risk of incident NHL (odds ratio for highest vs lowest quartile, 0.76), with the protective association found to be strongest for the 10-year exposure interval before diagnosis.
Epidemiologic evidence of a relationship between serum vitamin D levels and risk of NHL is inconsistent. In a case-control study nested within the AlphaTocopherol, Beta-Carotene Cancer Prevention Study cohort of 29,133 male smokers, 22 higher serum 25(OH)D 3 levels at baseline were not found to be associated with a reduced risk of lymphoid malignancies overall, but were associated with a reduced risk of NHL over the first 7 years of follow-up. However, in a larger pooled analysis of data from 10 cohort studies by the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, no association was found between serum 25(OH)D 3 levels at baseline and subsequent risk of NHL. 23 Evidence from prior studies of an association between vitamin D levels and prognosis in patients with hematologic malignancies is more robust. Lower vitamin D levels have been associated with worse overall survival in patients with acute myeloid leukemia, 24 chronic lymphocytic leukemia, 25 and NHL, 26, 27 as well as the NHL subtypes diffuse large B-cell lymphoma, 27 ,28 follicular lymphoma, 29 and T-cell lymphoma. 27, 30 Due to the sampling variability of our effect estimates for cancer-specific mortality after diagnosis, the results of the current study cannot definitively confirm or disconfirm these findings. However, the suggestive protective associations we observed for mortality attributable to lymphoid malignancy provide some support for these reports.
When comparing the results of the current study with those from prior studies, it should be noted that the dose of 400 IU/day of vitamin D3 in the WHI CaD trial represents a modest dose, and adherence was not ideal: 81% of participants took 50% of their doses (on average, at least 1 pill per day). For these reasons, the difference in the mean serum 25(OH)D 3 levels between the treatment arms at year 2 (24.3 ng/mL vs 18.2 ng/mL) was small in comparison with the considerable degree of between-person variability in serum 25(OH)D 3 levels assessed as a prognostic marker in prior epidemiologic studies. For example, prior studies of disease prognosis in hematologic malignancies have defined insufficient 25(OH)D 3 levels as <25 ng/mL, 25, 27 which would include the majority of WHI participants in the CaD active treatment arm after supplementation. The findings of the current study may not be generalizable to those with higher baseline levels of 25(OH)D 3 , or reflect the effects of more vigorous supplementation strategies.
Several biologic observations support a role for vitamin D as protective against hematologic malignancies. Vitamin D has effects on T cells, B cells, natural killer cells, and dendritic cells in the lymphoid compartment, in which it may impact the malignant transformation of these cells or affect their ability to mitigate the emergence of other malignant hematologic clones. 31 Vitamin D also decreases Janus-associated kinase-signal transducer and activator of transcription (JAK-STAT) pathway activation in vitro, providing a potential rationale for protective effects against myeloid malignancies. 32, 33 Furthermore, vitamin D supports the differentiation of myeloid blasts and facilitates apoptosis in lymphoid and leukemic cell lines. 34 The strengths of the current study include subject randomization to CaD supplementation or placebo; adjudication of study endpoints by trained clinicians blinded to treatment assignment; the large number of participants; and the extended length of follow-up, which was consistent with an induction period of 7 to 10 years as suggested by prior observational studies demonstrating protective associations for NHL risk. In addition, participant retention was high in the WHI CaD trial through year 10 of follow-up (79%).
The current study also has limitations. First, type I error is a possible explanation for the results herein due to the modest effect size and the fact that the current study was a secondary post hoc analysis of WHI trial data. Second, the low incidence of hematologic malignancies meant that we had limited power to assess the relationship between CaD treatment assignment and survival after diagnosis. Third, we were not able to evaluate the effect of CaD supplementation on the risk of subclinical hematopoietic disorders such as monoclonal gammopathy of undetermined significance (MGUS) because these were not outcomes adjudicated in the WHI trial. Finally, because the study intervention was a combination of doses of 1000 mg of calcium carbonate and 400 IU of vitamin D 3 daily, we were unable to attribute the protective associations observed in the current study solely to vitamin D. Although some observational data suggest possible protective associations between calcium intake and reduced cancer risk, 5 both the associations and the case for biological plausibility are strongest for digestive system cancers. 5, 35, 36 For hematopoietic malignancies, it is less biologically plausible that calcium supplementation would affect carcinogenesis. Although calcium does play an essential role in apoptotic signaling pathways, 37 serum and extracellular fluid calcium levels are tightly regulated 38 and would not be meaningfully changed by modest CaD supplementation in an unselected population of older women. 39 The results of the current post hoc analysis of data from a large and well-executed RCT demonstrate a protective effect on hematologic malignancy incidence with modest vitamin D and calcium supplementation in older women. Considered in absolute terms, the size of the effect is not likely to be clinically significant, but may have public health relevance when considered at the population level. The most consistent evidence of both cancer risk and prognosis was observed for lymphoid malignancies. Given the substantial associations between vitamin D insufficiency and inferior outcomes in patients with hematologic malignancies and the current interest in evaluating the role of vitamin D treatment of patients with these diseases, clinical trials investigating vitamin D supplementation currently are underway (ClinicalTrials.gov identifiers NCT02553447 and NCT02553447). The findings of the current analysis provide support for the further allocation of resources to vitamin D clinical trials.
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